Please assess the completion status of the following clinical trial:

Trial Title: A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be female, at least 18 years of age, but not older than 90 years, with advanced or metastatic HER2+ breast cancer and a life expectancy of more than 6 months~* Patient must have confirmed HER2 overexpression or gene-amplified tumor via immunohistochemistry \[IHC\] with IHC 3+ or IHC 2+ with confirmatory fluorescence in situ hybridization \[FISH\]+ or \[ISH\]+~* Patients must have had at least 1 line of anti-HER2 directed therapy either in the metastatic or early-stage disease setting~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion Criteria:~* Patient has had previous treatment with poziotinib.~* Patient has received anticancer chemotherapy, TKIs, biologics, immunotherapy, radiotherapy, or investigational treatment within 15 days. (There is no washout for hormonal therapy for breast cancer).~* Patient has a life expectancy less than 3 years due to other malignancies.~* Patient is pregnant or breast-feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Poziotinib (Type: EXPERIMENTAL): * Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~* Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD.

Based on this trial design, predict the completion outcome and termination type (if applicable).